Ascletis Bioscience

Ascletis is a commercial-stage innovative biopharmaceutical company listed on the Hong Kong Stock Exchange, specializing in the development and commercialization of therapies for viral diseases, non-alcoholic steatohepatitis (NASH/MASH), and oncology. The company achieved a significant milestone by launching Ganovo, the first domestically developed direct-acting antiviral for Hepatitis C in China. Its robust pipeline features ASC22, a first-in-class PD-L1 antibody for the functional cure of chronic Hepatitis B, and several metabolic-focused candidates like ASC40 and ASC41. Ascletis operates a fully integrated business model that spans from early-stage drug discovery to large-scale GMP manufacturing and commercial distribution. The company is also advancing treatments for dermatology, including a Phase 3 candidate for acne, and continues to expand its presence in the global liver disease market.